REGN
Strong BuyPremium GrowerAPPROVERegeneron Pharmaceuticals, Inc. · Healthcare · United States · $81.8B · Avg Vol: $566M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Regeneron clears the calibrated bar. All three legs are above the floor (Q69 V52 M52) and a buyback retiring 2.43% of shares provides substantial corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q69 is the strongest part of the case.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT REGENERON PHARMACEUTICALS, INC.
Read
Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious diseases, with a strong presence in areas like eye diseases, allergic/inflammatory conditions, and oncology. The company's proprietary VelocImmune antibody discovery platform and robust R&D capabilities enable the creation of blockbuster biologic drugs, establishing a significant competitive moat through intellectual property and scientific leadership. Regeneron's integrated approach from research to commercialization underpins its success.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.2B | 13.1B | 14.2B | 14.3B | 5.6% | 15.5B | 16.9B | 18.5B | 13.5% |
| EPS | 40.51 | 37.05 | 40.90 | 43.07 | 2.1% | 40.42 | 52.30 | 61.02 | 19.0% |
| Shares | 109.6M | 109.4M | 109.6M | 105.7M | -3.5% | 101.1M | — | — | — |
| Debt | 2.7B | 2.7B | 2.7B | 2.7B | 0.1% | 2.7B | — | — | — |
| Equity | 22.7B | 26.0B | 29.4B | 31.3B | 11.3% | — | — | — | — |
| Op CF | 5.0B | 4.6B | 4.4B | 5.0B | -0.2% | 4.7B | — | — | — |
| Inv CF | -3.8B | -3.2B | -2.5B | -629.1M | — | — | — | — | — |
| Fin CF | -1.0B | -1.8B | -2.2B | -3.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc.(you) | $81.8B | 85 | Strong Buy |
| ONC | BeOne Medicines AG | $41.5B | 87 | Strong Buy |
| CSL.AX | CSL Limited | $38.0B | 85 | Strong Buy |
| ARGX.BR | argenx SE | $64.5B | 74 | Buy |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| VRTX | Vertex Pharmaceuticals Incorporated | $137.3B | 68 | Buy |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $26.5B | 90 | Strong Buy |
| GMAB.CO | Genmab A/S | $20.8B | 80 | Strong Buy |
| INCY | Incyte Corporation | $25.2B | 96 | Strong Buy |
| 1801.HK | Innovent Biologics, Inc. | $23.9B | 71 | Buy |
Peer medians: ROE 2.7% · P/E 23.6x · Gross margin 52.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.